Kurma Partners Closes €215 Million Biofund IV to Back European BioTech Ventures From Paris

Why It Matters

The capital bolsters Europe’s capacity to translate cutting‑edge science into marketable therapies, strengthening regional competitiveness and strategic autonomy in a sector dominated by U.S. players.

Key Takeaways

• Kurma Partners closed Biofund IV at €215 M (~$232 M).
• Fund size up 35% from Biofund III’s €160 M (~$173 M).
• Cornerstone investors include CSL, EIF, and Bpifrance.
• Targeting ~20 European biotech deals, 11 already made.
• Biofund IV adds to €1 B total AUM for Kurma.

Pulse Analysis

Kurma Partners’ €215 million Biofund IV final close marks a significant inflection point for European life‑science financing. Backed by industry stalwart CSL, the European Investment Fund and Bpifrance, the fund expands Kurma’s capital pool by roughly 35% compared with Biofund III. This infusion arrives as Europe witnesses a broader surge of biotech capital—about €110 million (≈$119 million) in recent rounds across France, Germany, the Netherlands and the UK—signalling robust investor confidence in oncology, rare‑disease and next‑gen therapeutic platforms. By converting scientific breakthroughs into investable companies, Kurma helps bridge the notorious “valley of death” that often stalls European discoveries.

The strategic composition of Biofund IV’s backers underscores a coordinated push for European strategic autonomy in health innovation. CSL’s participation reflects a growing trend of pharma firms partnering with venture capital to secure early‑stage pipelines, while the EIF’s involvement aligns with the EU’s TechEU agenda to nurture home‑grown tech champions. For policymakers, the fund’s €1 billion AUM milestone illustrates how public‑private synergies can scale capital deployment, fostering a resilient biotech ecosystem capable of competing with U.S. and Asian rivals. Moreover, the fund’s focus on creating new companies via Argobio Studio adds a venture‑builder dimension, accelerating the formation of high‑potential startups.

Historically, Kurma’s earlier Biofunds have delivered notable exits—Amolyt to AstraZeneca, Emergence Therapeutics to Eli Lilly, and Corlieve to uniQure—validating its deal‑sourcing model. Biofund IV targets roughly twenty investments, already backing eleven firms spanning autoimmune, cardiac genetics, and cancer immunotherapy. As the portfolio matures, the fund could generate further M&A activity, bolstering Europe’s drug pipeline and delivering returns to limited partners. In sum, Biofund IV not only expands capital for promising biotech ventures but also reinforces Europe’s long‑term ambition to become a self‑sufficient leader in therapeutic innovation.